Chinese Pharma Company Xuanzhu Biopharmaceutical Takes Home Over US$100M in Series A

Xuanzhu Biopharmaceutical welcomes Chinese government’s State Development and Investment Corporation as an investor

Xuanzhu Biopharmaceutical, a subsidiary of China-based pharmaceutical company Sihuan Pharmaceutical Holdings, has raised RMB800 million (approximately US$115.6 million) in its Series A round of financing, according to a statement by the company today.

The funding was raised from Chinese state-owned investment company State Development and Investment Corporation (SDIC), a new investor in Xuanzhu Biopharmaceutical with a stake of 18.6%, the statement said.

“The joining of the SDIC is an affirmation of Xuanzhu Biopharmaceutical’s current achievements. We will continue to bring world-leading, unique and innovative therapeutic drugs to more clinical patients in the future,” President, R&D, at Xuanzhu Biopharmaceutical, said Dr Li Jiakui said in the statement.

“With the help of Sihuan Pharmaceutical’s extensive commercialization experience in China, as well as our outstanding R&D capabilities and localized development capabilities, we believe that Xuanzhu Biopharmaceutical can gain a competitive advantage in the ever-evolving clinical and regulatory environment in China,” he added.

The deal involves an equity incentive plan for Xuanzhu Biopharmaceutical’s management in building a drug R&D and production platform in China, the statement also said. Xuanzhu Biopharmaceutical and SDIC are also expected to collaborate in the future in this field.

Xuanzhu Biopharmaceutical is a drug research and development platform founded in 2002. It was acquired by Sihuan Pharmaceutical in 2012, and eventually became an independent spin-off of the company with a capital of RMB1.15 billion in 2018.

Apart from China, the company has a presence in the U.S. and Hong Kong, the statement noted.

“Xuanzhu Biopharmaceutical is deploying research and development of market-leading innovative drug, and is rapidly promoting clinical research and development and marketing, thus building a strong platform,” SDIC said in the statement.

“We are very happy to support Xuanzhu Biopharmaceutical’s highly efficient team at this exciting stage. They are using their expertise and capabilities to expand treatment options and benefit Chinese patients,” the company added.

Xuanzhu Biopharmaceutical has several products in its pipeline, some in the late clinical stage, covering oncology, diabetes, metabolic diseases, digestive system, male reproduction, and anti-infection.

Of these, its products Birociclib, a CDK4/6 inhibitor for advanced breast cancer, and Janagliflozin, an SGLT2 inhibitor for the treatment of diabetes, are the most promising, the statement noted.

“We are very pleased to see that SDIC has full confidence in Xuanzhu Biopharmaceutical’s ability in developing high-value innovative drugs,” Chief Commercial Officer of Xuanzhu Biopharmaceutical, Dr Leslie Boyd said in the statement.

“The new investment will make Xuanzhu capable of maintaining a good cooperative relationship with those partners who share the same values with us for a long time, and always use innovative therapies to continuously improve patients’ lives and medical standards,” Boyd added.

As of 2017, China was the world’s second largest pharmaceutical market, and also the biggest emerging market with its value expected to reach $175 billion by 2022.

Header image by Anshu A on Unsplash

SHARE THIS STORY

Share on facebook
Share on twitter
Share on linkedin
Share on email

RELATED POSTS

Elon Musk’s Neuralink Debuts Brain Chip Implant: A Bold Future with Ethical Questions

Elon Musk’s Neuralink is back in the spotlight with a major update: they’ve put a brain chip, called the Link, into a human for the first time. This small device has set its sights on monumental goals, such as helping people who’ve lost their limb functionality. Musk’s big dream doesn’t stop there—he wants the chip to boost our brains, improve our memory and eventually blend the human mind with artificial intelligence (AI).

Mercedes-Benz Launches the New Luxurious CLE Cabriolet

Mercedes-Benz has launched the CLE Cabriolet, building on its heritage of creating four-seater convertible vehicles. This new addition is characterized by its expressive design, advanced technology, and high-quality features, ensuring an enhanced driving experience. The model, which evolves from the CLE Coupé, stands out with its traditional fabric acoustic soft top and distinct high-quality details, making it uniquely positioned in the market. Designed to offer dynamic performance alongside exceptional daily comfort, the CLE Cabriolet supports year-round open-air enjoyment.

4 Companies Reusing Coffee Husk for Eco-Friendly Innovations

A daily cup of coffee is more than just a morning ritual—it’s a powerhouse of energy and health benefits. Beyond keeping you alert, coffee supports brain health, maintains liver function and may even lower the risk of depression. However, the journey of coffee from plantation to mug involves an energy-intensive process that produces significant waste, particularly coffee husks.

Fort Worth Hosts New LG Electronics Facility for EV Charger Assembly

LG Electronics has initiated its first U.S. production facility for electric vehicle (EV) charging stations in Fort Worth, Texas, aiming to bolster the national EV charging infrastructure and generate employment opportunities. The facility’s inauguration was marked by an event attended by Fort Worth Mayor Mattie Parker and LG executives Alec Jang, H.K. Suh and Nicolas Min. This development is part of LG’s strategy to expand its presence in the EV charger market by providing high-quality charging solutions and services.

KPMG Introduces “The Road to Leadership” along with Harvard Business School

KPMG in India and Harvard Business School Publishing Corporation (HBSPC) have announced a collaboration to launch “The Road to Leadership”, a program designed to empower mid-level managers with the skills and insights needed to ascend to leadership roles. This collaboration brings together HBSPC’s rich legacy in leadership education and KPMG’s deep industry experience, offering participants a unique blend of theoretical knowledge and practical insights tailored for the Indian context.